Pioneers in patient-based
drug discovery

Derisked drug candidates for next generation medicine.

Given the rising costs of drug discovery combined with high failure rates in late-stage clinical development, our proprietary pipeline of patient-based drug discovery programs aims at derisking next generation medicine for muscular and neurologic diseases with high medical needs.

At Ksilink, we design and apply patient-based cellular disease models applicable for large-scale phenotypic screening. Our proprietary drug discovery engine applies unique AI-boosted cellular profiling technologies to identify druggable targets and develop the most efficient compounds for novel treatment options. To leverage on this unique capacity, Ksilink has developed a network of academic and clinical sourcing throughout Europe to remain at the cutting edge of a fast-developing field.​

Testimonials from our strategic partners​

“We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”

Jacques Volckmann

Head of R&D, Sanofi, France

“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”

Wolfram Zimmermann

CSO, Myriamed GmbH, Germany

“We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”

Andreas Meyer-Lindenberg

Director and CEO, Central Institute of Mental Health, Germany

“We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”

Bert Klebl

Managing Director, Lead Discovery Center, Germany